| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0002253 | Activation of immune response | Increases phenotype | PMID:27933861 |
| GO:0003939 | L-iditol 2-dehydrogenase activity | Decreases phenotype | PMID:34118364 |
| GO:0004364 | Glutathione transferase activity | Decreases phenotype | PMID:34118364 |
| GO:0004457 | Lactate dehydrogenase activity | Increases phenotype | PMID:34118364 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:27919644; PMID:36878459 |
| GO:0006089 | Lactate metabolic process | Increases phenotype | PMID:34118364 |
| GO:0006749 | Glutathione metabolic process | Increases phenotype | PMID:27334974; PMID:34118364; PMID:36878459 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:27919644 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:27919644 |
| GO:0007283 | Spermatogenesis | Decreases phenotype | PMID:27334974; PMID:27919644; PMID:34118364 |
| GO:0008206 | Bile acid metabolic process | Affects phenotype | PMID:35835356 |
| GO:0010693 | Negative regulation of alkaline phosphatase activity | Increases phenotype | PMID:34118364 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:34118364 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:27919644 |
| GO:0034418 | Urate biosynthetic process | Increases phenotype | PMID:34118364 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:27334974; PMID:34118364; PMID:36878459 |
| GO:0042104 | Positive regulation of activated t cell proliferation | Increases phenotype | PMID:27933861 |
| GO:0043372 | Positive regulation of cd4-positive, alpha-beta t cell differentiation | Increases phenotype | PMID:27933861 |
| GO:0043378 | Positive regulation of cd8-positive, alpha-beta t cell differentiation | Increases phenotype | PMID:27933861 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:35835356; PMID:36878459 |
| GO:0045429 | Positive regulation of nitric oxide biosynthetic process | Increases phenotype | PMID:34118364 |
| GO:0045930 | Negative regulation of mitotic cell cycle | Affects phenotype | PMID:27919644 |
| GO:0046621 | Negative regulation of organ growth | Increases phenotype | PMID:34118364 |
| GO:0050878 | Regulation of body fluid levels | Decreases phenotype | PMID:34118364 |
| GO:0051347 | Positive regulation of transferase activity | Increases phenotype | PMID:34118364 |
| GO:0051348 | Negative regulation of transferase activity | Affects phenotype | PMID:34118364 |
| GO:0051353 | Positive regulation of oxidoreductase activity | Increases phenotype | PMID:34118364 |
| GO:0051354 | Negative regulation of oxidoreductase activity | Affects phenotype | PMID:34118364 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:36878459 |
| GO:0055072 | Iron ion homeostasis | Affects phenotype | PMID:36878459 |
| GO:0070265 | Necrotic cell death | Increases phenotype | PMID:36878459 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:36878459 |
| GO:0098727 | Maintenance of cell number | Decreases phenotype | PMID:34118364 |
| GO:0110111 | Negative regulation of animal organ morphogenesis | Increases phenotype | PMID:34118364 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:35835356; PMID:36878459 |
| GO:1901318 | Negative regulation of flagellated sperm motility | Increases phenotype | PMID:34118364 |
| GO:1901670 | Negative regulation of superoxide dismutase activity | Increases phenotype | PMID:34118364 |
| GO:1902512 | Positive regulation of apoptotic dna fragmentation | Increases phenotype | PMID:27334974 |
| GO:1903283 | Negative regulation of glutathione peroxidase activity | Increases phenotype | PMID:34118364 |
| GO:2000844 | Negative regulation of testosterone secretion | Increases phenotype | PMID:27334974 |
| GO:2001025 | Positive regulation of response to drug | Increases phenotype | PMID:34118364 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.